gilead glp-1 May 4, 2025: New study suggests more adverse events associated with compounded GLP-1s than standard formulations – Partnership for Safe Medicines This gentle HER Speaker Series: GLP 1

Discontinuation rates in everyday settings are also higher than whats reported in clinical trials, highlighting the importance of a more tailored approach

GLP-1 medications acted as metabolic correctors

Ive talked about the upsides of pharmacologically boosting GLP-1 activity in terms of weight loss, given the ravages of obesity, and Ive also discussed its downsides, including common gastrointestinal reactions and muscle loss, as well as the rarer or more speculative side effects such as thyroid cancer, pancreatitis, and pancreatic cancer

So we are addressing the concerns, questions, and misinformation we hear regarding medical weight loss treatments like GLP-1 in Kansas City

Clinical Evidence for Non-Diabetic Weight Loss The STEP trials, which enrolled predominantly non-diabetic participants, demonstrated that semaglutide produces average weight loss of 1022% of body weight over 68 weeks, depending on dose level

Makary said in a statement